Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ziad Ali, Cunyet Tegin & Rif S. El-Mallakh. (2020) Evaluating lurasidone as a treatment option for bipolar disorder. Expert Opinion on Pharmacotherapy 21:3, pages 253-260.
Read now
Read now
Michael E Thase, Peter Zhang, Catherine Weiss, Stine Rasmussen Meehan & Mary Hobart. (2019) Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opinion on Pharmacotherapy 20:15, pages 1907-1916.
Read now
Read now
Marc Kelliny, Paul E Croarkin, Katherine M Moore & William V Bobo. (2015) Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management 11, pages 1193-1212.
Read now
Read now
Borwin Bandelow, Michael Bauer, Eduard Vieta, Nizar El-Khalili, Urban Gustafsson, Willie R. Earley & Hans Eriksson. (2014) Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. The World Journal of Biological Psychiatry 15:2, pages 155-166.
Read now
Read now
Mazen K Ali & Raymond W Lam. (2011) Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 7, pages 39-49.
Read now
Read now
Articles from other publishers (61)
Nicholas T. Trapp, Benjamin D. Pace, Brandon Neisewander, Patrick Ten Eyck & Aaron D. Boes. (2023) A randomized trial comparing beam F3 and 5.5 cm targeting in rTMS treatment of depression demonstrates similar effectiveness. Brain Stimulation 16:5, pages 1392-1400.
Crossref
Crossref
Martin M. Monti, Norman M. Spivak, Brian L. Edlow & Yelena G. Bodien. (2023) What is a minimal clinically important difference for clinical trials in patients with disorders of consciousness? a novel probabilistic approach. PLOS ONE 18:8, pages e0290290.
Crossref
Crossref
Julia Große, Charlotte Huppertz, Astrid Röh, Viola Oertel, Sara Andresen, Niklas Schade, Franziska Goerke-Arndt, Anna Kastinger, Nikola Schoofs, Philipp Arthur Thomann, Karsten Henkel, Berend Malchow, Jens Plag, Aleksandra Terziska, Ralf Brand, Frank Helmig, Alexander Schorb, Dirk Wedekind, Maria Jockers-Scherübl, Frank Schneider, Moritz Bruno Petzold & Andreas Ströhle. (2023) Step away from depression—results from a multicenter randomized clinical trial with a pedometer intervention during and after inpatient treatment of depression. European Archives of Psychiatry and Clinical Neuroscience.
Crossref
Crossref
Catherine Elizabeth Carr, Emma Millard, Merve Dilgul, Cornelia Bent, Donald Wetherick, Jennifer French & Stefan Priebe. (2023) Group music therapy with songwriting for adult patients with long-term depression (SYNCHRONY study): a feasibility and acceptability study of the intervention and parallel randomised controlled trial design with wait-list control and nested process evaluation. Pilot and Feasibility Studies 9:1.
Crossref
Crossref
Michael Adair, Michael Cronquist Christensen, Ioana Florea, Henrik Loft & Andrea Fagiolini. (2023) Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. Journal of Affective Disorders 328, pages 345-354.
Crossref
Crossref
Eduardo Cumbo, Michael Adair, Daniel Oudin Åstrom & Michael Cronquist Christensen. (2023) Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Joshua D. Rosenblat, Froukje E. deVries, Zoe Doyle, Roger S. McIntyre, Gary Rodin, Camilla Zimmermann, Ernie Mak, Breffni Hannon, Christian Schulz-Quach, Aida Al Kindy, Zeal Patel & Madeline Li. (2023) A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study). Cancers 15:2, pages 400.
Crossref
Crossref
Hermann Spießl. (2022) Ein paar kritische Gedanken zu intranasalem EsketaminA few critical thoughts on intranasal esketamine. Der Nervenarzt 94:1, pages 63-64.
Crossref
Crossref
Heather Rozjabek, Nan Li, Holger Hartmann, Dong Jing Fu, Carla Canuso & Carol Jamieson. (2022) Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray. Journal of Patient-Reported Outcomes 6:1.
Crossref
Crossref
Guillaume Economos, Marine Alexandre, Elise Perceau-Chambard, Laurent Villeneuve, Fabien Subtil, Julie Haesebaert & Olivier Glehen. (2022) What is the effectiveness and safety of mirtazapine versus escitalopram in alleviating cancer-associated poly-symptomatology (the MIR-P study)? A mixed-method randomized controlled trial protocol. BMC Palliative Care 21:1.
Crossref
Crossref
Breno Souza-Marques, Manuela Telles, Gustavo C. Leal, Daniela Faria-Guimarães, Fernanda S. Correia-Melo, Ana Paula Jesus-Nunes, Flávia Vieira, Lucca Souza, Daniel Lins-Silva, Rodrigo P. Mello, Lívia Guerreiro-Costa, Igor D. Bandeira, Acioly L.T. Lacerda, Aline S. Sampaio & Lucas C. Quarantini. (2022) Esketamine for Unipolar Major Depression With Psychotic Features. Journal of Clinical Psychopharmacology 42:4, pages 408-412.
Crossref
Crossref
S. Spulber, F. Elberling, J. Svensson, M. Tiger, S. Ceccatelli & J. Lundberg. (2022) Patterns of activity correlate with symptom severity in major depressive disorder patients. Translational Psychiatry 12:1.
Crossref
Crossref
Mohit Chauhan, Rebecca Parry & William V Bobo. (2022) Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice. Neuropsychiatric Disease and Treatment Volume 18, pages 1175-1193.
Crossref
Crossref
Sichang Yang, Zongshi Qin, Xinjing Yang, Mei Yan Chan, Shuiyan Zhang, Peijing Rong, Xiaobing Hou, Guixing Jin, Fengquan Xu, Yong Liu & Zhang-Jin Zhang. (2022) Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation vs. Escitalopram for Patients With Mild-to-Moderate Depression (TECAS): Study Design for a Randomized Controlled, Non-inferiority Trial. Frontiers in Psychiatry 13.
Crossref
Crossref
Michael P Hengartner & Martin Plöderl. (2022) Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evidence-Based Medicine 27:2, pages 69-73.
Crossref
Crossref
Nathen A. Spitz, Patrick Ten Eyck, Krystal Nizar, Aaron D. Boes & Nicholas T. Trapp. (2022) Similar Outcomes in Treating Major Depressive Disorder With 10 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) Versus Intermittent Theta Burst Stimulation (iTBS): A Naturalistic Observational Study. Journal of Psychiatric Practice 28:2, pages 98-107.
Crossref
Crossref
Holger C. Bringmann, Aline Sulz, Philipp Ritter, Stefan Brunnhuber, Michael Bauer & René Mayer-Pelinski. (2021) Mantra meditation as adjunctive therapy in major depression: A randomized controlled trial. Journal of Affective Disorders Reports 6, pages 100232.
Crossref
Crossref
Michael Cronquist Christensen, Roger S. McIntyre, Ioana Florea, Henrik Loft & Andrea Fagiolini. (2021) Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. CNS Spectrums, pages 1-8.
Crossref
Crossref
Hermann Spießl. (2021) Spravato oder die Frage: „Wie viel darf ein Antidepressivum kosten?“. Psychiatrische Praxis 48:05, pages 227-230.
Crossref
Crossref
Norman A. S. Farb, Janet Murchison, Robert Madan, Hailey Goldberg, Cindy Grief, David Conn & Nasreen Khatri. (2021) Mindfulness-Based Stress Reduction Interventions for Mood in Older Adults: How Do Qualitative Experiences Inform Clinical Response?. Mindfulness 12:7, pages 1733-1747.
Crossref
Crossref
Lynda H. Powell, Kenneth E. Freedland & Peter G. KaufmannLynda H. Powell, Peter G. Kaufmann & Kenneth E. Freedland. 2021. Behavioral Clinical Trials for Chronic Diseases. Behavioral Clinical Trials for Chronic Diseases
209
236
.
. (2020) Esketamine for treatment-resistant depression. Drug and Therapeutics Bulletin 58:12, pages 183-188.
Crossref
Crossref
Christian Otte, Woo Ri Chae, Jan Nowacki, Michael Kaczmarczyk, Dominique Piber, Stefan Roepke, Stefanie Märschenz, Sandra Lischewski, Sein Schmidt, Barbara Ettrich, Hans Joergen Grabe, Ulrich Hegerl, Kim Hinkelmann, Tobias Hofmann, Deborah Janowitz, Klaus Junghanns, Kai G. Kahl, Jan Philipp Klein, Tillmann H. C. Krueger, Gregor Leicht, David Prvulovic, Andreas Reif, Daniel Schoettle, Maria Strauss, Anna Westermair, Tim Friede & Stefan M Gold. (2020) Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open 10:12, pages e040119.
Crossref
Crossref
Jeanette M. Johnstone, Andrew Hughes, Joshua Z. Goldenberg, Amy R. Romijn & Julia J. Rucklidge. (2020) Multinutrients for the Treatment of Psychiatric Symptoms in Clinical Samples: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 12:11, pages 3394.
Crossref
Crossref
Joyce A. Cramer, Sam Colman, Kathryn P. Anastassopoulos, Todd Grinnell, Darshan Mehta & G. Rhys Williams. (2020) Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results. Epilepsy & Behavior 112, pages 107312.
Crossref
Crossref
Karin Olsson, Erika Franzén & Anders Johansson. (2020) A Pilot Study of the Feasibility and Effects of Table Tennis Training in Parkinson Disease. Archives of Rehabilitation Research and Clinical Translation 2:3, pages 100064.
Crossref
Crossref
Paulo R. Shiroma, Paul Thuras, Joseph Wels, C. Sophia Albott, Christopher Erbes, Susannah Tye & Kelvin O. Lim. (2020) A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Translational Psychiatry 10:1.
Crossref
Crossref
Dávid Pintér, Annamária Juhász, Márk Harmat, József Janszky & Norbert Kovács. (2020) The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson’s Disease. Scientific Reports 10:1.
Crossref
Crossref
Florian Naudet & Ioana A Cristea. (2020) Approval of esketamine for treatment-resistant depression – Authors' reply. The Lancet Psychiatry 7:3, pages 235-236.
Crossref
Crossref
Melanie M Ashton, Olivia M Dean, Wolfgang Marx, Mohammadreza Mohebbi, Michael Berk, Gin S Malhi, Chee H Ng, Sue M Cotton, Seetal Dodd, Jerome Sarris, Malcolm Hopwood, Keshav Faye-Chauhan, Yesul Kim, Sarah R Dash, Felice N Jacka, Nitin Shivappa, James R Hebert & Alyna Turner. (2019)
Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive
N
-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial
. Australian & New Zealand Journal of Psychiatry 54:2, pages 159-172.
Crossref
Crossref
Mohammed S Salahudeen, Cameron M Wright & Gregory M Peterson. (2020) Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Therapeutic Advances in Drug Safety 11, pages 204209862093789.
Crossref
Crossref
P. Roux, E. Brunet-Gouet, M. Ehrminger, B. Aouizerate, V. Aubin, J. M. Azorin, F. Bellivier, T. Bougerol, P. Courtet, C. Dubertret, J. P. Kahn, M. Leboyer, E. Olié, B. Etain & C. Passerieux. (2020) Minimum clinically important differences for the Functioning Assessment Short Test and a battery of neuropsychological tests in bipolar disorders: results from the FACE-BD cohort. Epidemiology and Psychiatric Sciences 29.
Crossref
Crossref
C. Gastaldon, D. Papola, G. Ostuzzi & C. Barbui. (2020)
Esketamine clinical trials: reply to Maju
et al.
. Epidemiology and Psychiatric Sciences 29.
Crossref
Crossref
Jerome Sarris, Jenifer Murphy, Con Stough, David Mischoulon, Chad Bousman, Patricia MacDonald, Laura Adams, Sonia Nazareth, Georgina Oliver, Lachlan Cribb, Karen Savage, Ranjit Menon, Suneel Chamoli, Michael Berk, Chee H. Ng & Gerard J. Byrne. (2019) S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology 237:1, pages 209-218.
Crossref
Crossref
Simone N. Vigod, Kellie E. Murphy, Cindy-Lee Dennis, Tim F. Oberlander, Joel G. Ray, Zafiris J. Daskalakis & Daniel M. Blumberger. (2019) Transcranial direct current stimulation (tDCS) for depression in pregnancy: A pilot randomized controlled trial. Brain Stimulation 12:6, pages 1475-1483.
Crossref
Crossref
Faiza Siddiqui, Ulf Lindblad, Peter M Nilsson & Louise Bennet. (2019) Effects of a randomized, culturally adapted, lifestyle intervention on mental health among Middle-Eastern immigrants. European Journal of Public Health 29:5, pages 888-894.
Crossref
Crossref
Steve Chung, Saurabh R. Sinha, Aashit Shah, John M. Stern, Hailong Cheng, JungAh Jung, Todd Grinnell & David Blum. (2019) Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. Epilepsy Research 153, pages 59-65.
Crossref
Crossref
Marija Markovic, Alyssa Gallipani, Krina H. Patel & Megan Maroney. (2016) Brexpiprazole. Annals of Pharmacotherapy 51:4, pages 315-322.
Crossref
Crossref
Annamária Juhász, Zsuzsanna Aschermann, Péter Ács, József Janszky, Márton Kovács, Attila Makkos, Márk Harmat, Dalma Tényi, Kázmér Karádi, Sámuel Komoly, Annamária Takáts, Adrián Tóth, Helga Nagy, Péter Klivényi, György Dibó, Lívia Dézsi, Dénes Zádori, Ádám Annus, László Vécsei, Lajos Varannai & Norbert Kovács. (2017) Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: An open-label study. Parkinsonism & Related Disorders 37, pages 79-86.
Crossref
Crossref
Annamária Juhász, Gabriella Deli, Zsuzsanna Aschermann, József Janszky, Márk Harmat, Attila Makkos, Márton Kovács, Sámuel Komoly, István Balás, Tamás Dóczi, András Büki & Norbert Kovács. (2017) How Efficient Is Subthalamic Deep Brain Stimulation in Reducing Dyskinesia in Parkinson's Disease?. European Neurology 77:5-6, pages 281-287.
Crossref
Crossref
Gustaf Boström, Mia Conradsson, Carl Hörnsten, Erik Rosendahl, Nina Lindelöf, Henrik Holmberg, Peter Nordström, Yngve Gustafson & Håkan Littbrand. (2016) Effects of a high-intensity functional exercise program on depressive symptoms among people with dementia in residential care: a randomized controlled trial. International Journal of Geriatric Psychiatry 31:8, pages 868-878.
Crossref
Crossref
William V. Bobo, Jennifer L. Vande Voort, Paul E. Croarkin, Jonathan G. Leung, Susannah J. Tye & Mark A. Frye. (2016) KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. Depression and Anxiety 33:8, pages 698-710.
Crossref
Crossref
L. Samalin, M. Reinares, I. de Chazeron, C. Torrent, C. M. Bonnin, D. Hidalgo-Mazzei, A. Murru, I. Pacchiarotti, P. A. Geoffroy, F. Bellivier, P. M. Llorca & E. Vieta. (2016) Course of residual symptoms according to the duration of euthymia in remitted bipolar patients. Acta Psychiatrica Scandinavica 134:1, pages 57-64.
Crossref
Crossref
Marion Burckhardt, Max Herke, Tobias Wustmann, Stefan Watzke, Gero Langer & Astrid Fink. (2016) Omega-3 fatty acids for the treatment of dementia. Cochrane Database of Systematic Reviews 2016:4.
Crossref
Crossref
Gülşah Barğı, Meral Boşnak Güçlü, Zeynep Arıbaş, Şahika Zeynep Akı & Gülsan Türköz Sucak. (2015) Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Supportive Care in Cancer 24:2, pages 647-659.
Crossref
Crossref
Attila Makkos, Endre Pál, Zsuzsanna Aschermann, József Janszky, Éva Balázs, Katalin Takács, Kázmér Karádi, Sámuel Komoly & Norbert Kovács. (2016) High-Frequency Repetitive Transcranial Magnetic Stimulation Can Improve Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Neuropsychobiology 73:3, pages 169-177.
Crossref
Crossref
Sunny Chapel, Yu-Yuan Chiu, Jay Hsu, Josephine Cucchiaro & Antony Loebel. (2016) Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clinical Therapeutics 38:1, pages 4-15.
Crossref
Crossref
Mercedes P Jacobson, Ladislav Pazdera, Perminder Bhatia, Todd Grinnell, Hailong Cheng & David Blum. (2015) Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurology 15:1.
Crossref
Crossref
Michael R. Sperling, Jay Harvey, Todd Grinnell, Hailong Cheng & David Blum. (2015)
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase
III
study based in North America
. Epilepsia 56:4, pages 546-555.
Crossref
Crossref
Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, George Foussias & Gary Remington. (2015) Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 35:2, pages 128-133.
Crossref
Crossref
Mette Jensen, Ifeoma Nwando Agbata, Michelle Canavan & Geraldine McCarthy. (2015) Effectiveness of educational interventions for informal caregivers of individuals with dementia residing in the community: systematic review and meta-analysis of randomised controlled trials. International Journal of Geriatric Psychiatry 30:2, pages 130-143.
Crossref
Crossref
Natalia O. Dmitrieva, Denise Fyffe, Shubhabrata Mukherjee, Robert Fieo, Laura B. Zahodne, Jamie Hamilton, Guy G. Potter, Jennifer J. Manly, Heather R. Romero, Dan Mungas & Laura E. Gibbons. (2015) Demographic characteristics do not decrease the utility of depressive symptoms assessments: examining the practical impact of item bias in four heterogeneous samples of older adults. International Journal of Geriatric Psychiatry 30:1, pages 88-96.
Crossref
Crossref
Emma Bedson, Diana Bell, Daniel Carr, Ben Carter, Dyfrig Hughes, Andrea Jorgensen, Helen Lewis, Keith Lloyd, Andrew McCaddon, Stuart Moat, Joshua Pink, Munir Pirmohamed, Seren Roberts, Ian Russell, Yvonne Sylvestre, Richard Tranter, Rhiannon Whitaker, Clare Wilkinson & Nefyn Williams. (2014) Folate Augmentation of Treatment – Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technology Assessment 18:48, pages 1-160.
Crossref
Crossref
Jenni Hislop, Temitope E. Adewuyi, Luke D. Vale, Kirsten Harrild, Cynthia Fraser, Tara Gurung, Douglas G. Altman, Andrew H. Briggs, Peter Fayers, Craig R. Ramsay, John D. Norrie, Ian M. Harvey, Brian Buckley & Jonathan A. Cook. (2014) Methods for Specifying the Target Difference in a Randomised Controlled Trial: The Difference ELicitation in TriAls (DELTA) Systematic Review. PLoS Medicine 11:5, pages e1001645.
Crossref
Crossref
Gerhard Andersson, Hugo Hesser, Andrea Veilord, Linn Svedling, Fredrik Andersson, Owe Sleman, Lena Mauritzson, Ali Sarkohi, Elisabet Claesson, Vendela Zetterqvist, Mailen Lamminen, Thomas Eriksson & Per Carlbring. (2013) Randomised controlled non-inferiority trial with 3-year follow-up of internet-delivered versus face-to-face group cognitive behavioural therapy for depression. Journal of Affective Disorders 151:3, pages 986-994.
Crossref
Crossref
Michael Bauer, Roger S. McIntyre, Johan Szamosi & Hans Eriksson. (2013) Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. International Journal of Neuropsychopharmacology 16:8, pages 1755-1765.
Crossref
Crossref
Florian Naudet, Bruno Millet, Jean Michel Reymann & Bruno Falissard. (2013) Improving study design for antidepressant effectiveness assessment. International Journal of Methods in Psychiatric Research 22:3, pages 217-231.
Crossref
Crossref
Sarah C. Masson & Aaron M. Tejani. (2013) Minimum clinically important differences identified for commonly used depression rating scales. Journal of Clinical Epidemiology 66:7, pages 805-807.
Crossref
Crossref
Mark Sanford & Gillian M. Keating. (2012) Quetiapine. CNS Drugs 26:5, pages 435-460.
Crossref
Crossref
Endre Pal, Ferenc Nagy, Zsuzsanna Aschermann, Eva Balazs & Norbert Kovacs. (2010) The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study. Movement Disorders 25:14, pages 2311-2317.
Crossref
Crossref
Heidi Lempp, Graham Thornicroft, Morven Leese, Naomi Fearns, Helen Graves, Bernadette Khoshaba, Antonio Lasalvia, David Scott & Michele Tansella. (2009) Implications of long-term conditions for both mental and physical health: comparison of rheumatoid arthritis and schizophrenia. Quality of Life Research 18:6, pages 699-707.
Crossref
Crossref